Inbakicept

Identification

Name
Inbakicept
Accession Number
DB16479
Description
Not Available
Type
Biotech
Groups
Investigational
Synonyms
  • Inbakicept
External IDs
  • ALT-803
  • N-803
  • WHO 1102

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action

Inbakicept is a human IL-15 superagonist with immunostimulatory properties. Though a promising anti-cancer biologic, the drug is also being investigated as an HIV cure. It has the ability to reactivate latent virus, and has the potential to enhance anti-viral immune repsonses in these chronic infections.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
QN4LI58PJ5
CAS number
2135939-52-3

References

General References
  1. Webb GM, Molden J, Busman-Sahay K, Abdulhaqq S, Wu HL, Weber WC, Bateman KB, Reed JS, Northrup M, Maier N, Tanaka S, Gao L, Davey B, Carpenter BL, Axthelm MK, Stanton JJ, Smedley J, Greene JM, Safrit JT, Estes JD, Skinner PJ, Sacha JB: The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339. doi: 10.1371/journal.ppat.1008339. eCollection 2020 Mar. [PubMed:32163523]
  2. McBrien JB, Mavigner M, Franchitti L, Smith SA, White E, Tharp GK, Walum H, Busman-Sahay K, Aguilera-Sandoval CR, Thayer WO, Spagnuolo RA, Kovarova M, Wahl A, Cervasi B, Margolis DM, Vanderford TH, Carnathan DG, Paiardini M, Lifson JD, Lee JH, Safrit JT, Bosinger SE, Estes JD, Derdeyn CA, Garcia JV, Kulpa DA, Chahroudi A, Silvestri G: Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8(+) cells. Nature. 2020 Feb;578(7793):154-159. doi: 10.1038/s41586-020-1946-0. Epub 2020 Jan 22. [PubMed:31969705]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentAcute Myeloid Leukemia (AML)1
2RecruitingTreatmentAcute Myeloid Leukemia (AML)1
2RecruitingTreatmentAcute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentCervical Cancers / Colorectal Cancers / Head and Neck Squamous Cell Carcinoma (HNSCC) / Hepatocellular Carcinoma / Malignant Neoplasm of Stomach / Melanomas / Microsatellite Instability / Mismatch Repair Deficiency / Neuroendocrine Carcinoma of the Skin / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma / Small Cell Lung Cancer (SCLC) / Transitional Cell Carcinoma1
2RecruitingTreatmentColorectal Cancers / Small Bowel Cancers1
2RecruitingTreatmentHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)1
2RecruitingTreatmentMalignant Neoplasm of Pancreas1
2RecruitingTreatmentNeuroendocrine Carcinoma of the Skin1
2WithdrawnTreatmentHigh-Risk Acute Myeloid Leukemia / Myelodysplastic Syndrome / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Treatment-Related Acute Myeloid Leukemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Drug created on January 21, 2021 01:47 / Updated on February 21, 2021 18:55